Oppenheimer Maintains Outperform on Perspective Therapeutics, Raises Price Target to $1.2
Portfolio Pulse from richadhand@benzinga.com
Oppenheimer analyst Jeff Jones maintains an Outperform rating on Perspective Therapeutics (AMEX:CATX) and raises the price target from $1 to $1.2.
May 19, 2023 | 11:35 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Oppenheimer analyst Jeff Jones maintains an Outperform rating on Perspective Therapeutics and raises the price target from $1 to $1.2.
The news of Oppenheimer maintaining an Outperform rating and raising the price target for Perspective Therapeutics (AMEX:CATX) from $1 to $1.2 is positive for the stock. This indicates that the analyst has a positive outlook on the company's performance and believes that the stock price will increase in the short term. As a result, this news is likely to have a positive impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100